Denali Therapeutics News and Activities

Presence

Denali Therapeutics develops medicines for neurodegenerative and lysosomal diseases. It provides drug discovery, clinical development, and related research services for patients, healthcare providers, and pharmaceutical partners.

Denali Therapeutics products and services overview:

Neurodegenerative therapies
Lysosomal disease treatments
Drug discovery
Clinical development
Research partnerships

Revenue: ~$72 million

Employees: 460

Headquarters: South San Francisco, United States (USA)

Denali Therapeutics is one of the...

Denali Therapeutics is a company listed under the stock ticker DNLI (US).

Executives

View the org chart displaying its 26 main executives

Most searched biographies at Denali Therapeutics

Popular executive movements at Denali Therapeutics

Erica Kratz, Senior Vice President, Regulatory Affairs and Head of Development Quality Assurance, has left the company (posted on June 2 2026).
Carole Ho, Chief Medical Officer, has left the company (posted on December 4 2025).
Carole Ho, who is Chief Medical Officer will soon leave the company (posted on November 7 2025).

Click here to view some more movements at Denali Therapeutics

Create your alert
to follow the executive moves at Denali Therapeutics.